Status:
COMPLETED
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborating Sponsors:
Biogen
Conditions:
Multiple Sclerosis
Optic Neuritis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The current study is a continuation of the 5 year extension study of the phase III CHAMPS study (see reference). This study was designed to determine if immediate initiation of therapy with Interferon...
Detailed Description
The CHAMPS study determined that immediate initiation of interferon beta 1a therapy (AVONEX) immediately following a first clinical demyelinating event in high risk patients (i.e. those with at least ...
Eligibility Criteria
Inclusion
- Previous participation in CHAMPS study
- Participation in a study site willing to participate in the CHAMPIONS10 extension study
- Willingness to enroll in the CHAMPIONS 10 extension
- Willingness to sign informed consent
Exclusion
- Discovery of an alternative neurological disorder other than MS as a cause of initial neurological symptoms
- A severe systemic disease with likely mortality within 3 years
Key Trial Info
Start Date :
February 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
155 Patients enrolled
Trial Details
Trial ID
NCT00179478
Start Date
February 1 2001
End Date
March 1 2009
Last Update
September 6 2017
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
MS Treatment Center at Griffin Hospital
Derby, Connecticut, United States, 06418
2
Jaeb Center for Health Research
Tampa, Florida, United States, 33647
3
MS Center of Atlanta
Atlanta, Georgia, United States, 30327
4
Beta Research, Inc
Elk Grove, Illinois, United States, 60007